Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity (2023 - 2025)
Historic Liabilities and Shareholders Equity for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $190.8 million.
- Contineum Therapeutics' Liabilities and Shareholders Equity fell 1165.88% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $784.8 million, marking a year-over-year increase of 1352.55%. This contributed to the annual value of $212.8 million for FY2024, which is 6324.38% up from last year.
- According to the latest figures from Q3 2025, Contineum Therapeutics' Liabilities and Shareholders Equity is $190.8 million, which was down 1165.88% from $182.9 million recorded in Q2 2025.
- Contineum Therapeutics' 5-year Liabilities and Shareholders Equity high stood at $221.4 million for Q2 2024, and its period low was $123.6 million during Q1 2024.
- Moreover, its 3-year median value for Liabilities and Shareholders Equity was $194.6 million (2025), whereas its average is $184.5 million.
- As far as peak fluctuations go, Contineum Therapeutics' Liabilities and Shareholders Equity surged by 6324.38% in 2024, and later crashed by 1737.8% in 2025.
- Quarter analysis of 3 years shows Contineum Therapeutics' Liabilities and Shareholders Equity stood at $130.4 million in 2023, then skyrocketed by 63.24% to $212.8 million in 2024, then dropped by 10.34% to $190.8 million in 2025.
- Its Liabilities and Shareholders Equity stands at $190.8 million for Q3 2025, versus $182.9 million for Q2 2025 and $198.3 million for Q1 2025.